Science.bio Shutdown (January 2026)

In mid-January 2026, Science.bio — a prominent grey-market vendor of research peptides and nootropics — ceased operations, becoming one of the first major vendor closures in what would become a broader wave of shutdowns in early 2026.

Background

Science.bio operated as a research chemical vendor, selling peptides, SARMs, and nootropic compounds labeled for research use only. The company had built a reputation in the biohacking and peptide communities for:

• Third-party testing: Published certificates of analysis for products
• Diverse product line: Peptides, SARMs, nootropics, and other research compounds
• Accessible pricing: Competitive prices relative to other grey-market vendors
• Community presence: Active engagement in Reddit and forum communities

Key Products

Science.bio sold a range of peptides including:

• BPC-157
• TB-500
• CJC-1295
• Ipamorelin
• Selank
• Semax
• Various SARMs and nootropic compounds

The Shutdown

• Operations ceased approximately January 15, 2026
• Website was taken offline or converted to a static page
• No detailed public statement explaining the closure
• Customer fulfillment of pending orders was reportedly handled before shutdown

Context and Significance

The Science.bio shutdown preceded the larger Peptide Sciences closure by roughly two months. Together, these closures signaled a turning point for the grey-market peptide industry:

1. Regulatory environment: FDA enforcement actions against peptide vendors had been escalating since the Category 2 designations
2. Legal exposure: Vendors selling compounds for obvious human use under a “research only” label faced increasing legal risk
3. Industry signal: The closure of established vendors suggested either direct regulatory pressure or a rational assessment that the legal risks had become untenable

Impact

• Medium impact relative to later closures — Science.bio was significant but smaller than Peptide Sciences
• Customers migrated to remaining vendors, increasing demand concentration
• The closure was an early warning sign that the grey-market peptide ecosystem was under serious pressure
• Nootropics community also affected, as Science.bio carried non-peptide products

Related Notes

• Peptide-Sciences-Shutdown-March-2026 — larger vendor shutdown two months later
• FDA-Category-2-Designations-2023-2024 — regulatory backdrop driving vendor closures
• FDA-Reclassification-Announcement-Feb-2026 — Kennedy reclassification announced between the two shutdowns